---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-009107"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T05:59:05.815728+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MaxCyte Q1 revenue $8.6M (-26% YoY), net loss $10.9M; cuts FY23 revenue growth guidance to 8-12%

## Summary
- Total revenue $8.6M, down 26% YoY; core business revenue $7.8M, down 19%.
- Net loss $10.9M vs $4.1M; EBITDA loss $12.2M vs $3.7M.
- FY23 total revenue growth guidance lowered to 8%-12%; core revenue growth 5%-10%.
- Two new SPL partnerships signed: Walking Fish Therapeutics (May) and Catamaran Bio (Jan).
- Douglas J. Swirsky appointed CFO, effective immediately.

## SEC filing metadata
- accession: 0001558370-23-009107
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000155837023009107/0001558370-23-009107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000155837023009107/mxct-20230510x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-009107
- JSON: https://secwatch.observer/filing/0001558370-23-009107.json
- Plain text: https://secwatch.observer/filing/0001558370-23-009107.txt

## Key facts
- Earnings Releases
  MAXCYTE, INC. reported First quarter ended March 31, 2023 results: net income Net loss of $10.9 million.
  - Period: First quarter ended March 31, 2023
  - Net income: Net loss of $10.9 million
  - Result: reported results
  source text: Total revenue for the first quarter of 2023 was $8.6 million, compared to $11.6 million in the first quarter of 2022, representing a decline of 26%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1287098/000155837023009107/0001558370-23-009107-index.htm
- Earnings Releases
  MAXCYTE, INC. reported First quarter ended March 31, 2023 results: net income Net loss of $10.9 million.
  - Period: First quarter ended March 31, 2023
  - Net income: Net loss of $10.9 million
  - Result: reported results
  source text: First quarter 2023 net loss was $10.9 million compared to net loss of $4.1 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1287098/000155837023009107/0001558370-23-009107-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.